Literature DB >> 23589911

India's patent case victory rattles Big Pharma.

Patralekha Chatterjee.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23589911     DOI： 10.1016/s0140-6736(13)60826-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  1 in total

1.  Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.

Authors:  Ya-Chen Tina Shih; Jorge E Cortes; Hagop M Kantarjian
Journal:  Lancet Haematol       Date:  2019-06-14       Impact factor: 18.959
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.